Safety by design: Biosafety and biosecurity in the age of synthetic genomics.

Autor:	Hoffmann SA; Manchester Institute of Biotechnology, University of Manchester, 131 Princess Street, Manchester M1 7DN, UK., Diggans J; Twist Bioscience, 681 Gateway Boulevard, South San Francisco, CA 9408, USA., Densmore D; Department of Electrical and Computer Engineering, Boston University, 610 Commonwealth Avenue, Boston, MA 02215, USA., Dai J; CAS Key Laboratory of Quantitative Engineering Biology, Guangdong Provincial Key Laboratory of Synthetic Genomics and Shenzhen Key Laboratory of Synthetic Genomics, Shenzhen Institute of Synthetic Biology, Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China., Knight T; Ginkgo Bioworks, 27 Drydock Avenue, Boston, MA 02210, USA., Leproust E; Twist Bioscience, 681 Gateway Boulevard, South San Francisco, CA 9408, USA., Boeke JD; Institute for Systems Genetics, and Department of Biochemistry & Molecular Pharmacology, NYU Langone Health, 435 East 30th Street, New York, NY 10016, USA.; Department of Biomedical Engineering, NYU Tandon School of Engineering, Brooklyn, NY 11201, USA., Wheeler N; Institute of Microbiology and Infection, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK., Cai Y; Manchester Institute of Biotechnology, University of Manchester, 131 Princess Street, Manchester M1 7DN, UK.
Jazyk:	angličtina
Zdroj:	IScience [iScience] 2023 Feb 10; Vol. 26 (3), pp. 106165. Date of Electronic Publication: 2023 Feb 10 (Print Publication: 2023).
DOI:	10.1016/j.isci.2023.106165
Abstrakt:	Technologies to profoundly engineer biology are becoming increasingly affordable, powerful, and accessible to a widening group of actors. While offering tremendous potential to fuel biological research and the bioeconomy, this development also increases the risk of inadvertent or deliberate creation and dissemination of pathogens. Effective regulatory and technological frameworks need to be developed and deployed to manage these emerging biosafety and biosecurity risks. Here, we review digital and biological approaches of a range of technology readiness levels suited to address these challenges. Digital sequence screening technologies already are used to control access to synthetic DNA of concern. We examine the current state of the art of sequence screening, challenges and future directions, and environmental surveillance for the presence of engineered organisms. As biosafety layer on the organism level, we discuss genetic biocontainment systems that can be used to created host organisms with an intrinsic barrier against unchecked environmental proliferation. Competing Interests: D.D. is a co-founder of Lattice Automation, Inc. and Asimov Inc. Both companies create engineered biological systems using software and automation. J.D.B. is a Founder and Director of CDI Labs, Inc., a Founder of and consultant to Neochromosome, Inc, a Founder, SAB member of and consultant to Re-Open Diagnostics, LLC, and serves or served on the Scientific Advisory Board of the following: Sangamo Therapeutics, Inc., Modern Meadow, Inc., Rome Therapeutics, Inc., Sample6, Inc., Tessera Therapeutics, Inc. and the Wyss Institute. T.K. is co-founder of Ginkgo Bioworks, Inc. EL is CEO and co-founder of Twist Bioscience, Inc., and J.D. is an employee of Twist Bioscience, Inc. (© 2023 The Author(s).)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu